



NDA 21-976/S-017

SUPPLEMENT APPROVAL

Tibotec, Inc.
Attention: Charles Zezza Ph.D., MBA
Director
J&J Pharmaceutical Research and Development (J&J PRD)
On behalf of Tibotec, Inc.
920 Route 202
Raritan, NJ 08869

Dear Dr. Zezza:

Please refer to your Supplemental New Drug Application (sNDA) dated February 19, 2010, received March 3, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PREZISTA® (darunavir) 75 mg, 150 mg, 400 mg and 600 mg Tablets.

We acknowledge receipt of your amendments dated March 23, 2010, May 4, 2010, May 5, 2010, May 21, 2010, June 1, 2010, June 16, 2010, July 6, 2010, July 23, 2010, August 13, 2010, September 16, 2010, September 24, 2010, October 8, 2010, October 26, 2010, November 19, 2010, December 3, 2010 and December 7, 2010.

This Prior Approval supplemental new drug application provides for a new dosing regimen, 800/100 mg darunavir/ritonavir, once daily, in treatment-experienced HIV-1 infected patients with no darunavir resistance associated substitutions based on the results of Study TMC114-C229. The Patient Package Insert was revised to include the new dosing regimen and to provide a more user friendly label to prevent and/or reduce medication errors. In addition, all references to the 300 mg tablets were deleted and Hepatotoxicity and Severe Skin Reactions sections were added to Patient Counseling-Instructions for Use of the Package Insert.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert, text for the patient package insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements and any annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to < 3 years because there is evidence strongly suggesting that the drug product would be unsafe in this pediatric group.

We are deferring submission of your pediatric study of once a day dosing in treatment-experienced patients between ages 3 and < 18 years for this application because this product is ready for approval for use in adults and the pediatric study has not been completed.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacey Min, Pharm.D., Regulatory Project Manager, at (301) 796-4253.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY S MURRAY
12/13/2010